Vaccine by Bender, Thomas John et al.
Hepatitis B vaccine immunogenicity among adults vaccinated 
during an outbreak response in an assisted living facility—
Virginia, 2010
Thomas John Bendera, Umid Sharapovb, Okey Utahc, Jian Xingb, Dale Hub, Jolanta 
Rybczynskab, Jan Drobeniucb, Saleem Kamilib, Philip R. Spradlingb, and Anne C. 
Moormanb,*
aEpidemic Intelligence Service Program, The Office of Surveillance, Epidemiology, and 
Laboratory Services, Centers for Disease Control, Atlanta, GA, United States
bDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, United 
States
cVirginia Department of Health, Richmond, VA, United States
Abstract
Background—Failure to adhere to infection control guidelines, especially during assisted 
monitoring of blood glucose, has caused multiple hepatitis B outbreaks in assisted living facilities 
(ALFs). In conjunction with the response to such an outbreak at an ALF (“Facility X”) where most 
residents had neuropsychiatric disorders, we evaluated seroprotection rates conferred by hepatitis 
B vaccine and assessed the influence of demographic factors on vaccine response.
Methods—Residents were screened for hepatitis B and C infection, and those susceptible were 
vaccinated against hepatitis A and hepatitis B with one dose of TWINRIX™ (GSK) given at 0, 1, 
and 7 months. Blood samples were collected 1–2 months after receipt of the third vaccine dose to 
test for antibody to hepatitis B surface antigen (anti-HBs).
Results—Of the 27 residents who had post-vaccination blood specimens collected, 22 (81%) 
achieved anti-HBs concentrations ≥10 mIU/mL. Neither age nor neuropsychiatric comorbidity was 
a significant determinant of seroprotection. Geometric mean concentration was lower among 
residents aged 60–74 years (74.3 mIU/mL) than among residents aged 46–59 years (105.3 
mIU/mL) but highest among residents aged ≥75 years (122.5 mIU/mL). The effect of diabetes on 
vaccination response could not be examined because 16/17 (94%) diabetic residents had HBV 
infection by the time of investigation.
Conclusions—Adult vaccine recipients of all ages, even those over 60 years of age, 
demonstrated a robust capacity for achieving hepatitis B seroprotection in response to the 
combined hepatitis A/hepatitis B vaccine. The role for vaccination in interrupting HBV 
transmission during an outbreak remains unclear, but concerns about age-related response to 
*Corresponding author. Tel.: +1 404 718 8567., amoorman@cdc.gov (A.C. Moorman). 
Ethical considerations
The investigation followed the guidelines of the U.S. Department of Health and Human Services regarding protection of human 
subjects.
HHS Public Access
Author manuscript
Vaccine. Author manuscript; available in PMC 2017 December 07.
Published in final edited form as:
Vaccine. 2014 February 07; 32(7): 852–856. doi:10.1016/j.vaccine.2013.12.018.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
hepatitis B vaccine may be insufficient to justify foregoing vaccination of susceptible residents of 
ALFs.
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1. Introduction
Hepatitis B virus (HBV) is transmitted by percutaneous or mucosal exposure to blood or 
bodily fluids from an infected person. Assisted living facilities (ALFs) provide long-term 
residential care to a growing number of adults needing assistance with activities of daily 
living. A substantial proportion of ALF residents have diabetes, many of whom will undergo 
assisted monitoring of blood glucose (AMBG) [1]. Performing AMBG requires use of 
fingerstick devices and blood glucose meters, which frequently become contaminated with 
blood [2,3]. Infection control guidelines for safe blood glucose monitoring have been 
available since 1990, and guidelines targeting long-term care settings were published in 
2005 [4]. Lapses in infection control during AMBG (e.g., reuse of fingerstick devices) have 
resulted in outbreaks of HBV infection among residents of long-term care facilities across 
the United States [4–15]. Among 30 HBV outbreaks that occurred in long-term care 
facilities (i.e., nursing homes or ALFs) and were reported to the Centers for Disease Control 
and Prevention (CDC) during 1996–2012, 26 (87%) were linked to breaches in infection 
control practice during AMBG [14]. In response to these outbreaks, in 2011 the Advisory 
Committee on Immunization Practices (ACIP) published new guidelines recommending that 
all previously unvaccinated adults under age 60 with diabetes be vaccinated against hepatitis 
B [16]. Because of scant data on the effectiveness of hepatitis B vaccination among adults 
aged ≥60 years the recommendation for this age group was for vaccination at the discretion 
of the treating clinician after assessing their risk and the likelihood of an adequate immune 
response to vaccination [16].
Hepatitis B vaccination is an effective measure to prevent HBV infection and is 
recommended for adults who are at high risk for infection [17]. Previously identified high-
risk groups also include residents and staff of facilities housing developmentally disabled 
persons [18–22]. Four of the 30 HBV outbreaks described above occurred in long-term care 
facilities in which most residents had neuropsychiatric disorders. Of these, only two were 
linked to infection control lapses during AMBG [11,13,14].
The effectiveness of hepatitis B vaccination for interrupting HBV transmission during an 
outbreak remains unclear because vaccination typically requires administration of three 
doses over a 6-month period, and completion of the series can be undermined by resident 
transfers between facilities. Even assuming completion of the vaccination series, adults aged 
≥60 years might be less likely to achieve seroprotection (hepatitis B antibody [anti-HBs] ≥10 
mIU/mL [16]) after receipt of hepatitis B vaccine than has been demonstrated among adults 
aged <40 years [23–28]. Therefore, we evaluated the immunogenicity of bivalent vaccine 
against hepatitis A and B administered to residents during a HBV outbreak at ALF “Facility 
X” and assessed the influence of demographic factors on vaccine response.
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2. Materials and methods
2.1. Study population
In January 2010, the Virginia Department of Health (VDH) received reports of two HBV 
infections (one acute case detected through routine hemodialysis screening, and one chronic 
case report) among residents of a single 160-bed ALF. Both patients had diabetes and 
received AMBG. Most residents of this ALF had neuropsychiatric disorders. VDH began an 
investigation with assistance from CDC to determine the number of ALF residents infected 
with HBV, identify modes of transmission, and implement control and prevention measures 
which included HBV vaccination [13]. The protocol for post-vaccination response testing 
was reviewed and approved by VDH and CDC Institutional Review Boards; written 
informed consent was signed by all participating patients or their conservators if the patient 
was unable to provide informed consent on his or her own behalf.
2.2. Serologic testing and vaccine administration
We collected an initial blood sample from all ALF residents who consented to initial 
screening or, for those residents unable to consent, whose conservators provided consent. 
Specimens were tested at CDC Division of Viral Hepatitis Laboratory for hepatitis B surface 
antigen (HBsAg), total core antibody (anti-HBc), IgM core antibody (IgM-anti-HBc), and 
surface antibody (anti-HBs) by using VITROS® ECi Immunodiagnostic System (Ortho-
Clinical Diagnostics, Inc., Rochester, NY). Based upon results from serologic testing of 
these pre-vaccination blood samples, residents were classified as acutely or chronically 
infected, immune, or susceptible to HBV infection according to standard criteria (Fig. 1) [5].
Patients who were susceptible to HBV infection who consented to vaccination or, for those 
residents unable to consent whose conservators provided consent, were vaccinated using a 
23-gauge one-inch needle in the right or left deltoid muscles with one 1-mL dose of 
TWINRIX™ provided by VDH (GlaxoSmithKline Biologicals, lot numbers: 
AHBVB640BA, AHABB174AA, AHABB167BA, AHABB162CA, AHABB189AB, 
AHABB185AA) on a 0, 1, 7 month schedule [17]. (The third dose, usually given at 6 
months, was delayed by 1 month due to logistical challenges.)
Because of logistical constraints only those vaccinated patients who were able to give 
informed consent without the assistance of a conservator were approached for consent to 
post-vaccination testing. Blood samples were collected at the standard time period for 
assessing serologic response to hepatitis B vaccine, 1–2 months after receipt of the third 
dose [17]. Anti-HBs concentrations ≥10 mIU/mL were considered indicative of 
seroprotection [17].
2.3. Demographic data
We examined facility health records of all current residents to obtain basic demographic 
(age, sex, and race) data. Information on clinical characteristics that might affect vaccine 
response (e.g., smoking, body mass index, alcohol use, renal disease, liver disease, HIV 
status, use of immunosuppressive drugs or chemotherapy, and other comorbid conditions) 
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was often missing from facility records because ALFs in Virginia are not required to 
maintain complete medical records.
2.4. Statistical analysis
Differences in the proportion of residents with adequate serologic response to hepatitis B 
vaccine (anti-HBs concentration ≥10 mIU/mL) based upon demographic characteristics 
were assessed and compared using Fisher’s exact test, with a p-value <0.05 considered 
statistically significant. For the purpose of summarizing the stimulated immunity for this 
population, quantitative anti-HBs concentrations were calculated as geometric mean 
concentrations (GMCs) with 95% confidence intervals (95% CIs). Each anti-HBs 
concentration value was log transformed and values below 1 mIU/mL were assigned a value 
of 1 mIU/mL before log transformation. SAS v9.2 (SAS Institute, Inc., Cary, NC) was used 
for statistical analysis.
3. Results
Among 139 residents present in the ALF in March 2010, HBV serologic status was 
determined for 126 (91%) (Fig. 1). Of these, 19 (15%) were HBV infected (5 chronic; 14 
acute), 33 (26%) were immune (24 had evidence of past infection and 9 of previous 
vaccination), and 74 (59%) appeared susceptible to infection as indicated by an anti-HBs 
level <10 mIU/mL. Prevalence of diabetes necessitating receipt of AMBG was 13% among 
these residents, and 16/17 (94%) diabetic residents had experienced HBV infection by the 
time of investigation. Among the 61 susceptible residents (82%) who consented to 
vaccination and completed the 3-dose vaccination series, 27 (44%) consented to 
measurement of vaccine response. The anti-HBs GMC among the 27 residents was 91.7 
mIU/mL (95% confidence interval, 35.17–239.2). Among these patients, 22 (81%) achieved 
anti-HBs concentrations ≥10 mIU/mL. Non-response status was shared with the five 
remaining patients’ physicians for consideration of re-vaccination, but re-vaccination and 
assessment of further response was not included in the protocol.
The median age of the 27 vaccinated residents was 60 years (range: 46–86 years). More men 
than women, but similar numbers of whites and blacks, were vaccinated (Table 1). None of 
the vaccinated residents had diabetes. The demographic characteristics (age, sex, and race) 
of the 47 (64%) susceptible residents who did not complete vaccination or did not have post-
vaccination serological testing were similar to those 27 (36%) who completed vaccination 
and post-vaccination serological testing; all p-values were >0.05. Susceptible patients who 
did not have post-vaccination testing were likely to have a more severe neuropsychiatric 
disorder (e.g., history of traumatic brain injury) because only patients able to provide 
consent without healthcare conservators were approached for post-vaccination testing. 
Common comorbid conditions among the vaccinated and unvaccinated patients included 
schizophrenia, depression, and hypertension. The one HBV-susceptible patient with diabetes 
declined vaccination.
Age was not a significant determinant of seroprotection. The proportion of residents who 
developed seroprotection was lower among residents aged 60–74 years (10/12 [75%]) than 
among residents aged 46–59 years (9/12 [83%]), but all three residents aged ≥75 years 
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developed seroprotection. Likewise, the GMC was lower among residents aged 60–74 years 
(74.3 mIU/mL) than among residents aged 46–59 years (105.3 mIU/mL), but highest among 
the three residents aged ≥75 (122.5 mIU/mL).
4. Discussion
During an outbreak of HBV infection at an ALF where most residents had neuropsychiatric 
disorders [13], bivalent hepatitis B/hepatitis A vaccine was administered to residents who 
were identified as susceptible to HBV infection and willing to be vaccinated. Seroprotection 
(anti-HBs concentration ≥10 mIU/mL) was achieved by 81% of residents who were 
vaccinated and willing to have their anti-HBs concentration measured after receipt of the 
third vaccine dose.
We did not detect any new infections after re-testing for hepatitis B markers at re-screening 
approximately 1 month after the second vaccine dose or at post-vaccination testing 1–2 
months past completion of the third dose of vaccine. Receipt of AMBG was the principal 
risk factor for acquiring HBV infection during this outbreak [13]. Inappropriate reuse of 
fingerstick devices on multiple residents was so efficient at transmitting HBV from resident 
to resident in this setting that only one resident with diabetes who received AMBG remained 
susceptible to infection. That resident declined to be vaccinated. Thus we cannot provide 
data on response to vaccination among persons with diabetes in this population.
In our study of ALF residents aged 46–86 years, age was not a significant determinant of 
seroprotection 1–2 months following a 3-dose vaccine series. In the few published studies 
that have assessed the response to hepatitis B vaccine among older adults (aged ≥60 years) 
reported seroprotection rates vary from 30% to 80% and depend on characteristics of the 
study population, vaccination history, vaccination schedule, and type of vaccine [23–31]. 
Some studies have shown poor response to bivalent hepatitis B/hepatitis A vaccine among 
elderly populations [23,29]. However, another study found higher response rates [24], with 
an approximately 65–70% response rate overall to simultaneous or combination hepatitis B 
and hepatitis A vaccine among persons 61–81 years of age in an unpublished sub-analysis 
[31].
Response to bivalent hepatitis A/B vaccine administered at standard dosing and schedule 
was also assessed during a 2010 HBV outbreak in two skilled nursing homes in another 
state; of these 86 residents aged 45–101, only 29 (34%) demonstrated seroprotective anti-
HBs levels [29]. Surprisingly in this study the response rate among the younger individuals 
under age 60 (33%) was no better than among those older; this may be due to the multiple 
comorbid conditions present among these persons whose care required residence in a skilled 
nursing facility. Response to monovalent hepatitis B vaccine administered at standard dosing 
and schedule was also assessed during a 2011 ALF HBV outbreak in which only 6/22 (27%) 
diabetic and/or memory-impaired residents aged 58–92 demonstrated seroprotective anti-
HBs levels, although response testing was delayed by 1–2 months (unpublished data, Watson 
J, Myrick-West A, Virginia Department of Health, Richmond, Virginia). In another recent 
study of response to monovalent hepatitis B vaccine among a population of ALF residents in 
Houston, TX, seroprotection was achieved by only 30% (7 of 23) of tested vaccine recipients 
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aged 70–89 [30]. In contrast, among the small number (n = 4) of residents aged 70 or greater 
in our study, all responded to the bivalent vaccine.
Several factors might have contributed to the high proportion of seroprotection achieved 
among residents in this study. First, unlike other studies [30] in which an accelerated (0, 1, 4 
months) vaccination schedule was implemented as part of the outbreak response effort, we 
used a 0, 1, 7 months vaccination schedule. Delaying the third dose beyond 4 months might 
have achieved a better booster effect. Second, data on most clinical characteristics that might 
affect vaccine response (e.g., smoking, body mass index, etc.) were missing from facility 
records. Third, age has been found to be a significant predictor of seroprotection in other 
study populations [30], and the majority of adults resident at this ALF were not significantly 
older than 60 years (median age 60) which likely favored the high proportion of 
seroprotection. Our sample size, particularly of residents aged ≥75 years, was small and 
limited to persons who could consent for themselves, thus estimates may not be widely 
generalizable. However, the data available from other studies for residents over 75 years old, 
while sparse, indicate that the development of seroprotection is achievable at least for some 
older adults [23–31].
In addition to characteristics of our study population that may have resulted in higher 
seroprotection, this study has some other potential limitations. It is possible some persons 
vaccinated in this study might have been previously vaccinated in the past without 
documentation in the currently available medical chart. In such vaccine recipients the 
response to vaccination would actually have been a response to revaccination with preserved 
immune memory in the absence of detectable antibody, which could have falsely elevated 
our estimate of primary vaccine response. Self-reported data on previous hepatitis B 
vaccination was not collected from the vaccinated residents because of logistical constraints 
and concerns about the reliability of patient recall for specific vaccinations received in the 
possibly quite distant past.
In the absence of a more immunogenic hepatitis B vaccine, adults anticipated to be at risk 
for bloodborne pathogen exposure are more likely to benefit from vaccination at earlier ages 
when immune response is most robust [16]. Adults with diabetes who do not currently 
require daily glucose monitoring might eventually require such monitoring, with or without 
assistance; recipients of AMBG in ALFs are at increased risk of bloodborne pathogen 
exposure [3,5,7,29] when infection control practices in such facilities are compromised [14]. 
In an effort to address this problem, ACIP recently recommended that all previously 
unvaccinated adults with diabetes aged 19 through 59 years be vaccinated against hepatitis B 
as soon as possible after a diagnosis of diabetes is made [16]. Persons with mental illness, if 
housed in a congregate setting for protracted periods, may also be at increased risk for HBV 
infection [18–22]. However, outbreaks have occurred among neuropsychiatric ALF 
populations linked with AMBG as well as other infection control breaches and patient risk 
behavior [11,14,32,33]. Protection of a growing and vulnerable ALF population should 
include interventions such as improved infection control oversight at ALFs, appropriate 
training of staff members performing AMBG, and prompt investigation of acute HBV 
infections [11].
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At this ALF, vaccine recipients without diabetes aged 60–86 years of age demonstrated a 
robust capacity for achieving sero-protection in response to the hepatitis B vaccine by 
standard measures [17]. The role for vaccination in interrupting HBV transmission during an 
outbreak remains unclear because of the timeline required for vaccine series completion and 
immunogenicity, but concerns about age-related response to hepatitis B vaccine may be 
insufficient to justify foregoing vaccination of susceptible residents.
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Fig. 1. 
Participant flow chart for hepatitis B screening and vaccination—Virginia, 2010. ALF, 
assisted living facility; HBV, hepatitis B virus; anti-HBs, antibody to hepatitis B surface 
antigen; anti-HBc, antibody to hepatitis B core antigen; HBsAg, hepatitis B surface antigen; 
immune, anti-HBs ≥10 mIU/mL. 1 Serologic markers indicating chronic infection: positive 
hepatitis B surface antigen (HBsAg) and total hepatitis B core antibody (anti-HBc), negative 
hepatitis B IgM core antibody (IgM anti-HBc). 2 Serologic markers indicating acute 
infection: positive HBsAg and IgM anti-HBc. One resident was determined to have acute 
infection based on a well-documented HBsAg seroconversion even though IgM-anti-HBc 
remained negative. 3 Serologic markers indicating immunity to hepatitis B due to past 
infection: positive hepatitis B antibody to surface antigen (anti-HBs) and total hepatitis B 
core antibody (anti-HBc). 4 Serologic markers indicating immunity to hepatitis B due to past 
vaccination: positive anti-HBs (level ≥10 mIU/mL) and anti-HBc negative. 5 Seroprotective 
response defined as anti-HBs ≥10 mIU/mL.
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